Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. plans to adjust certain sub-projects within its "Innovative Drug R&D Project" to enhance the efficiency of fundraising usage while maintaining the total investment amount for the project [1][2] Fundraising Overview - The company issued 24,760,000 shares at a price of RMB 42.92 per share, raising a total of RMB 1,062.70 million, with a net amount of RMB 995.91 million after deducting issuance costs [1] - The funds are managed in a dedicated account as per regulatory requirements [1] Project Adjustments - The first adjustment of fundraising amounts was made on June 7, 2022, due to the net amount being lower than initially planned [2] - A second adjustment was approved on April 4, 2024, to further optimize the allocation of funds for the "Innovative Drug R&D Project" and the "R&D Production Base Construction Project" [2] Current Fund Usage - As of June 30, 2025, the cumulative investment in the projects has reached RMB 99.51 million, with the R&D production base construction project exceeding its planned investment due to interest income from cash management [3][5] Sub-Project Adjustments - The company has decided to suspend the further development of the HP501 sub-project, a small molecule chemical innovative drug, due to increased competition in the market [6] - Remaining funds of RMB 121.73 million will be redirected to ongoing projects HP518 and HP537 [6] Ongoing Projects - HP518 is the first oral AR PROTAC drug in clinical trials in China, with a completed Phase I study and ongoing Phase II trials [7][8] - HP537 has received approval for clinical trials in China and the U.S. [8] Rationale for Adjustments - The decision to adjust sub-projects is based on market competition and the company's strategic planning to enhance fundraising efficiency [6][9] Impact of Adjustments - The adjustments are expected to improve overall R&D efficiency and resource allocation without significantly impacting the company's current operating performance [9] Decision-Making Process - The adjustments were approved by the company's board and supervisory committee and will be submitted for shareholder approval [9][10]
海创药业: 关于首次公开发行股票部分募投项目子项目调整的公告